Candel F, Barreiro P, Salavert M, Cabello A, Fernandez-Ruiz M, Perez-Segura P
Viruses. 2023; 15(7).
PMID: 37515137
PMC: 10383267.
DOI: 10.3390/v15071449.
Agrati C, Bartolini B, Bordoni V, Locatelli F, Capobianchi M, Di Caro A
Front Immunol. 2023; 14:1147871.
PMID: 36969202
PMC: 10035572.
DOI: 10.3389/fimmu.2023.1147871.
Lopes Marques C, Ribeiro S, Albuquerque C, de Sousa Studart S, Ranzolin A, de Andrade N
Adv Rheumatol. 2022; 62(1):45.
PMID: 36419163
PMC: 9685130.
DOI: 10.1186/s42358-022-00268-x.
Ammitzboll C, Thomsen M, Andersen J, Bartels L, Hermansen M, Johannsen A
Mod Rheumatol. 2022; 33(4):777-785.
PMID: 35860843
PMC: 9384499.
DOI: 10.1093/mr/roac069.
Jung Y, Kwon M, Choi H
BMJ Open. 2021; 11(10):e054753.
PMID: 34620675
PMC: 8507409.
DOI: 10.1136/bmjopen-2021-054753.
Perceived Risk and Associated Shielding Behaviors in Patients With Rheumatoid Arthritis During the Coronavirus 2019 Pandemic.
Cook C, Cox H, Fu X, Zhang Y, Stone J, Choi H
ACR Open Rheumatol. 2021; 3(12):834-841.
PMID: 34498436
PMC: 8653208.
DOI: 10.1002/acr2.11340.
Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19).
Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V
Eur Cytokine Netw. 2021; 32(1):8-14.
PMID: 34346869
PMC: 8491178.
DOI: 10.1684/ecn.2021.0463.
Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France.
Felten R, Scherlinger M, Guffroy A, Poindron V, Meyer A, Giannini M
Arthritis Res Ther. 2021; 23(1):188.
PMID: 34256812
PMC: 8276223.
DOI: 10.1186/s13075-021-02565-0.
Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up.
Gamboa-Cardenas R, Barzola-Cerron S, Toledo-Neira D, Reategui-Sokolova C, Pimentel-Quiroz V, Zevallos-Miranda F
Clin Rheumatol. 2021; 40(11):4725-4734.
PMID: 34189675
PMC: 8241466.
DOI: 10.1007/s10067-021-05833-1.
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study.
Shin Y, Shin J, Moon S, Jin H, Kim S, Yang J
Lancet Rheumatol. 2021; 3(10):e698-e706.
PMID: 34179832
PMC: 8213376.
DOI: 10.1016/S2665-9913(21)00151-X.
Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease.
Shenoy P, Ahmed S, Shanoj K, Shenoy V, Damodaran D, Menon A
Clin Rheumatol. 2021; 40(11):4665-4670.
PMID: 34155573
PMC: 8216872.
DOI: 10.1007/s10067-021-05801-9.
Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis.
Brito-Zeron P, Gracia-Tello B, Robles A, Alguacil A, Bonet M, De-Escalante B
Viruses. 2021; 13(6).
PMID: 34071924
PMC: 8228115.
DOI: 10.3390/v13061000.
Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic.
Tam L, Tanaka Y, Handa R, Li Z, Lorenzo J, Louthrenoo W
Int J Rheum Dis. 2021; 24(6):733-745.
PMID: 33945214
PMC: 8206920.
DOI: 10.1111/1756-185X.14124.
COVID-19 Among Patients With Inflammatory Rheumatic Diseases.
Esatoglu S, Tascilar K, Babaoglu H, Bes C, Yurttas B, Akar S
Front Immunol. 2021; 12:651715.
PMID: 33936073
PMC: 8086428.
DOI: 10.3389/fimmu.2021.651715.
Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry.
Del Mar Ayala Gutierrez M, Rubio-Rivas M, Romero Gomez C, Montero Saez A, Perez de Pedro I, Homs N
J Clin Med. 2021; 10(9).
PMID: 33922777
PMC: 8123043.
DOI: 10.3390/jcm10091844.
Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center.
Spinella A, Magnani L, de Pinto M, Marvisi C, Parenti L, Bajocchi G
Clin Med Insights Circ Respir Pulm Med. 2021; 15:11795484211001349.
PMID: 33795941
PMC: 7975443.
DOI: 10.1177/11795484211001349.
Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis.
Wang Q, Liu J, Shao R, Han X, Su C, Lu W
Rheumatol Int. 2021; 41(5):851-861.
PMID: 33687528
PMC: 7941871.
DOI: 10.1007/s00296-021-04803-9.
Management Issues of Sarcoidosis in the Time of Coronavirus Disease 2019.
Tana C, Schiavone C, Cipollone F, Giamberardino M
Chest. 2021; 159(3):1306-1307.
PMID: 33678261
PMC: 7930726.
DOI: 10.1016/j.chest.2020.09.267.
Inflammatory arthritis in patients with COVID-19.
Conway R, Konig M, Graef E, Webb K, Yazdany J, Kim A
Transl Res. 2021; 232:49-59.
PMID: 33626415
PMC: 7897406.
DOI: 10.1016/j.trsl.2021.02.010.
COVID-19 Incidence in Patients With Immunomediated Inflammatory Diseases: Influence of Immunosuppressant Treatments.
Soldevila-Domenech N, Tio L, Llorente-Onaindia J, Martin-Garcia E, Nebot P, de la Torre R
Front Pharmacol. 2021; 11:583260.
PMID: 33519443
PMC: 7845571.
DOI: 10.3389/fphar.2020.583260.
